

Randy D Gascoyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3645709/publications.pdf>

Version: 2024-02-01

711
papers

92,576
citations

315

138
h-index

326

287
g-index

741
all docs

741
docs citations

741
times ranked

60808
citing authors

#	ARTICLE	IF	CITATIONS
1	Circos: An information aesthetic for comparative genomics. <i>Genome Research</i> , 2009, 19, 1639-1645.	2.4	9,003
2	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
3	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	0.6	3,574
4	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	13.9	3,474
5	Stromal Gene Signatures in Large-B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2008, 359, 2313-2323.	13.9	1,564
6	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. <i>Nature Genetics</i> , 2010, 42, 181-185.	9.4	1,504
7	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	13.9	1,443
8	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. <i>Nature</i> , 2011, 476, 298-303.	13.7	1,428
9	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	13.7	1,402
10	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	13.9	1,293
11	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	13.7	1,292
12	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3121-3127.	0.8	1,203
13	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2007, 109, 1857-1861.	0.6	1,193
14	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	13.9	1,141
15	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	4.2	1,002
16	Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. <i>Cell</i> , 2010, 142, 699-713.	13.5	894
17	Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. <i>Journal of Clinical Oncology</i> , 2005, 23, 5027-5033.	0.8	874
18	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	3.3	868

#	ARTICLE	IF	CITATIONS
19	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	7.7	848
20	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	13.9	824
21	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
22	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. <i>Science</i> , 2008, 319, 1676-1679.	6.0	784
23	ALK ⁺ anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ⁻ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2008, 111, 5496-5504.	0.6	784
24	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	13.7	759
25	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	7.7	706
26	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	0.6	693
27	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2017, 390, 298-310.	6.3	615
28	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
29	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	3.2	577
30	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009, 114, 3533-3537.	0.6	566
31	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. <i>Blood</i> , 2006, 108, 3295-3301.	0.6	559
32	Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. <i>Blood</i> , 2011, 117, 2451-2459.	0.6	556
33	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , 2011, 471, 377-381.	13.7	551
34	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , 2009, 114, 2273-2279.	0.6	523
35	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518
36	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology, The</i> , 2015, 16, 1111-1122.	5.1	483

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. <i>Blood</i> , 1999, 93, 3913-3921.	0.6	464
38	Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma. <i>Blood</i> , 1997, 90, 244-251.	0.6	451
39	Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases. <i>Blood</i> , 1997, 89, 2067-2078.	0.6	448
40	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015, 125, 22-32.	0.6	445
41	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	0.6	435
42	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). <i>Blood</i> , 2005, 106, 2169-2174.	0.6	427
43	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, 200-207.	0.8	426
44	The tumour microenvironment in B cell lymphomas. <i>Nature Reviews Cancer</i> , 2014, 14, 517-534.	12.8	417
45	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.	0.6	376
46	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015, 21, 1199-1208.	15.2	359
47	Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. <i>Journal of Clinical Oncology</i> , 2011, 29, 1812-1826.	0.8	350
48	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. <i>Blood</i> , 2013, 122, 1256-1265.	0.6	349
49	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	0.6	348
50	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	1.7	345
51	Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. <i>Journal of Clinical Oncology</i> , 2013, 31, 1970-1976.	0.8	335
52	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	0.8	334
53	Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5165-5169.	0.8	333
54	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , 2005, 106, 4315-4321.	0.6	330

#	ARTICLE	IF	CITATIONS
55	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
56	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- κ B pathways in subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2008, 111, 3701-3713.	0.6	315
57	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , 2012, 119, 1963-1971.	0.6	313
58	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	0.8	313
59	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2011, 118, 148-155.	0.6	308
60	Pharmacological and genomic profiling identifies NF- κ B-targeted treatment strategies for mantle cell lymphoma. <i>Nature Medicine</i> , 2014, 20, 87-92.	15.2	303
61	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	0.6	296
62	ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. <i>Blood</i> , 2003, 102, 2568-2573.	0.6	281
63	Peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 6756-6767.	0.6	278
64	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 961-968.	0.8	277
65	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	13.7	276
66	EZH2 mutations are frequent and represent an early event in follicular lymphoma. <i>Blood</i> , 2013, 122, 3165-3168.	0.6	274
67	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	0.8	271
68	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
69	Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1607-1614.	0.8	264
70	Pathogenesis of follicular lymphoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 3424-3431.	3.9	264
71	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. <i>Cancer Cell</i> , 2010, 18, 590-605.	7.7	263
72	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 165, 159-166.	1.9	262

#	ARTICLE	IF	CITATIONS
73	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , 2010, 116, 5247-5255.	0.6	262
74	Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 1740-1745.	0.8	261
75	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2014, 123, 2062-2065.	0.6	259
76	Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 618-626.	0.6	257
77	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	0.8	257
78	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	0.8	256
79	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. <i>Blood</i> , 2016, 128, 1490-1502.	0.6	255
80	Loss of signalling via $\text{C}\dot{\text{I}}\pm 13$ in germinal centre B-cell-derived lymphoma. <i>Nature</i> , 2014, 516, 254-258.	13.7	253
81	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006, 107, 4207-4213.	0.6	248
82	Whole-Genome Analysis and HLA Genotyping of Enteropathy-Type T-Cell Lymphoma Reveals 2 Distinct Lymphoma Subtypes. <i>Gastroenterology</i> , 2007, 132, 1902-1911.	0.6	240
83	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
84	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo. <i>Cancer Cell</i> , 2012, 22, 812-824.	7.7	229
85	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	0.6	226
86	Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. <i>Blood</i> , 2009, 113, 3754-3764.	0.6	226
87	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	7.7	218
88	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	7.7	213
89	Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. <i>Annals of Oncology</i> , 2006, 17, 123-130.	0.6	212
90	Loss of BAF250a (<i>ARID1A</i>) is frequent in high-grade endometrial carcinomas. <i>Journal of Pathology</i> , 2011, 224, 328-333.	2.1	210

#	ARTICLE	IF	CITATIONS
91	Comparison of Cytogenetic Analysis, Southern Analysis, and Polymerase Chain Reaction for the Detection of t(14; 18) in Follicular Lymphoma. <i>American Journal of Clinical Pathology</i> , 1995, 103, 472-478.	0.4	207
92	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548.	0.6	205
93	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	13.5	204
94	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , 2016, 30, 197-213.	7.7	200
95	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. <i>Leukemia</i> , 2007, 21, 2332-2343.	3.3	198
96	Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2011, 29, 1452-1457.	0.8	197
97	HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. <i>Nature Immunology</i> , 2010, 11, 265-272.	7.0	196
98	A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. <i>Annals of Oncology</i> , 2007, 18, 129-135.	0.6	190
99	The molecular pathogenesis of primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2011, 118, 2659-2669.	0.6	189
100	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2003, 101, 4539-4546.	0.6	188
101	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012, 120, 3280-3287.	0.6	188
102	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , 2016, 13, e1002197.	3.9	185
103	<i>Helicobacter pylori</i> and MALT Lymphoma. <i>Gastroenterology</i> , 2005, 128, 1579-1605.	0.6	184
104	IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2015, 126, 1741-1752.	0.6	184
105	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	0.6	184
106	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1046-1052.	0.6	182
107	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. <i>Cancer Discovery</i> , 2013, 3, 1002-1019.	7.7	180
108	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , 2014, 46, 329-335.	9.4	180

#	ARTICLE	IF	CITATIONS
109	Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 793-799.	0.8	178
110	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009, 114, 826-834.	0.6	177
111	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	0.6	177
112	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007, 204, 633-643.	4.2	176
113	Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	0.8	176
114	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
115	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
116	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. <i>Blood</i> , 2010, 115, 289-295.	0.6	173
117	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
118	Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6370-6378.	0.8	172
119	International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 3383-3388.	0.8	171
120	Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation. <i>Journal of Clinical Oncology</i> , 1999, 17, 1558-1558.	0.8	169
121	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
122	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
123	MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. <i>Blood</i> , 2001, 97, 3902-3909.	0.6	166
124	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1216-1222.	0.8	166
125	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	7.7	163
126	Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	0.8	161

#	ARTICLE	IF	CITATIONS
127	Acquired <i>TNFRSF14</i> Mutations in Follicular Lymphoma Are Associated with Worse Prognosis. <i>Cancer Research</i> , 2010, 70, 9166-9174.	0.4	160
128	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
129	Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. <i>Journal of Clinical Oncology</i> , 2014, 32, 3096-3102.	0.8	159
130	Homozygous Deletions at Chromosome 9p21 Involving p16 and p15 Are Associated With Histologic Progression in Follicle Center Lymphoma. <i>Blood</i> , 1998, 91, 4677-4685.	0.6	158
131	<i>MYC</i> and <i>BCL2</i> protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>British Journal of Haematology</i> , 2014, 165, 382-391.	1.2	157
132	Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4211-4216.	0.8	154
133	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. <i>Blood</i> , 2010, 116, 418-427.	0.6	152
134	<i>BCL2</i> Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	3.2	152
135	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
136	A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. <i>Annals of Oncology</i> , 2007, 18, 116-121.	0.6	151
137	<i>FOXO1</i> is a tumor suppressor in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 3503-3511.	0.6	149
138	Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , 2008, 140, 516-526.	1.2	145
139	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. <i>Blood</i> , 2012, 119, 5118-5125.	0.6	145
140	Impact of dual expression of <i>MYC</i> and <i>BCL2</i> by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	0.6	145
141	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of <i>SETD2</i> . <i>Journal of Experimental Medicine</i> , 2017, 214, 1371-1386.	4.2	144
142	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13447-13454.	3.3	143
143	Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). <i>Genes Chromosomes and Cancer</i> , 2001, 30, 375-382.	1.5	142
144	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. <i>British Journal of Haematology</i> , 2007, 136, 286-293.	1.2	142

#	ARTICLE	IF	CITATIONS
145	Transformation of follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 147-163.	0.7	142
146	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 121, 3666-3674.	0.6	139
147	Mutation and genomic deletion status of ataxia telangiectasia mutated(ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2352-2357.	3.3	138
148	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89.	0.6	138
149	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. <i>Modern Pathology</i> , 2011, 24, 1586-1597.	2.9	137
150	Prognostic Factors in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2902-2913.	0.8	136
151	TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies. <i>Journal of Immunology</i> , 2000, 165, 5084-5096.	0.4	135
152	BCL2 mutations in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2012, 26, 1383-1390.	3.3	135
153	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	3.2	135
154	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. <i>Blood</i> , 2009, 113, 3773-3780.	0.6	133
155	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
156	Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 427-432.	1.5	131
157	MALT Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 241-258.	0.9	130
158	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2008, 112, 3425-3433.	0.6	130
159	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. <i>Cancer Discovery</i> , 2014, 4, 480-493.	7.7	130
160	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , 2005, 11, 1065-72.	3.2	130
161	MYC and Aggressive B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2011, 18, 219-228.	2.4	129
162	Recurrent targets of aberrant somatic hypermutation in lymphoma. <i>Oncotarget</i> , 2012, 3, 1308-1319.	0.8	127

#	ARTICLE	IF	CITATIONS
163	Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size. <i>Journal of Clinical Oncology</i> , 2008, 26, 5170-5174.	0.8	126
164	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011, 17, 4125-4135.	3.2	126
165	Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: Correlation with 3q27 and 18q21 chromosomal abnormalities. <i>Human Pathology</i> , 1999, 30, 803-808.	1.1	125
166	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. <i>Blood</i> , 2001, 98, 2837-2844.	0.6	125
167	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. <i>Blood</i> , 2013, 121, 3161-3164.	0.6	124
168	Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. <i>Blood</i> , 2009, 113, 137-148.	0.6	122
169	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. <i>Blood</i> , 2010, 116, 953-961.	0.6	122
170	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 120, 3530-3540.	0.6	122
171	Organochlorines and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2007, 121, 2767-2775.	2.3	121
172	Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. <i>British Journal of Haematology</i> , 2003, 120, 424-433.	1.2	118
173	Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. <i>Blood</i> , 2010, 115, 775-777.	0.6	117
174	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	0.6	117
175	U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation. , 1997, 30, 236-244.		116
176	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. <i>Human Molecular Genetics</i> , 2004, 13, 1827-1837.	1.4	115
177	Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 195-204.	1.5	114
178	Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. <i>Blood</i> , 2006, 108, 311-318.	0.6	113
179	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	0.8	113
180	The whole-genome landscape of Burkitt lymphoma subtypes. <i>Blood</i> , 2019, 134, 1598-1607.	0.6	113

#	ARTICLE	IF	CITATIONS
181	High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. <i>Blood</i> , 2005, 106, 1473-1478.	0.6	112
182	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. <i>Blood</i> , 2008, 112, 3126-3129.	0.6	112
183	Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. <i>Cell Reports</i> , 2015, 13, 1418-1431.	2.9	112
184	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	0.6	112
185	Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. <i>Lancet</i> , The, 1999, 354, 1698-1699.	6.3	111
186	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and tanford in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 . <i>British Journal of Haematology</i> , 2013, 161, 76-86.	1.2	111
187	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014, 123, 1681-1690.	0.6	110
188	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	0.6	110
189	Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. <i>Genome Biology</i> , 2015, 16, 18.	3.8	107
190	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	0.6	103
191	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	1.5	102
192	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	0.8	102
193	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. <i>Nature Communications</i> , 2018, 9, 4001.	5.8	102
194	Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. <i>Bone Marrow Transplantation</i> , 1998, 22, 981-987.	1.3	101
195	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. <i>Clinical Cancer Research</i> , 2015, 21, 3428-3435.	3.2	101
196	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. <i>Journal of Clinical Investigation</i> , 2010, 120, 4569-4582.	3.9	101
197	Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 461-469.	1.2	100
198	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	1.7	100

#	ARTICLE	IF	CITATIONS
199	Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency. <i>Journal of Clinical Oncology</i> , 2002, 20, 197-204.	0.8	99
200	Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?. <i>PLoS ONE</i> , 2013, 8, e78812.	1.1	99
201	t(11;18)(q21;q21.1): A recurring translocation in lymphomas of mucosa-associated lymphoid tissue (malt)?. <i>Genes Chromosomes and Cancer</i> , 1992, 4, 183-187.	1.5	98
202	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012, 119, 4939-4948.	0.6	97
203	Homozygous Deletions at Chromosome 9p21 Involving p16 and p15 Are Associated With Histologic Progression in Follicle Center Lymphoma. <i>Blood</i> , 1998, 91, 4677-4685.	0.6	97
204	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2019, 134, 802-813.	0.6	96
205	Long-term outcomes for patients with limited stage follicular lymphoma. <i>Cancer</i> , 2010, 116, 3797-3806.	2.0	94
206	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , 2008, 111, 5509-5514.	0.6	93
207	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	7.7	93
208	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , 2015, 126, 2118-2127.	0.6	91
209	Mantle cell lymphoma in the ocular adnexal region. <i>Ophthalmology</i> , 2005, 112, 114-119.	2.5	89
210	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	0.6	89
211	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. <i>Leukemia</i> , 2017, 31, 83-91.	3.3	87
212	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90- ¹²⁵ Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86
213	A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. <i>Leukemia</i> , 2007, 21, 1532-1544.	3.3	85
214	Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). <i>British Journal of Haematology</i> , 2010, 151, 143-151.	1.2	85
215	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
216	CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma: a population-based study from British Columbia. <i>British Journal of Haematology</i> , 2014, 167, 608-617.	1.2	84

#	ARTICLE	IF	CITATIONS
217	Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. <i>Blood</i> , 2011, 118, 4585-4590.	0.6	83
218	Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. <i>Blood</i> , 2012, 120, 4635-4644.	0.6	83
219	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , 2014, 123, 1699-1708.	0.6	83
220	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. <i>Haematologica</i> , 2008, 93, 1327-1334.	1.7	80
221	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. <i>British Journal of Haematology</i> , 2005, 131, 223-230.	1.2	78
222	Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. <i>British Journal of Haematology</i> , 2017, 176, 210-221.	1.2	78
223	Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 106-112.	2.1	77
224	MicroRNA profiles of t(14;18) negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011, 118, 5550-5558.	0.6	77
225	Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. <i>Blood</i> , 2005, 106, 349-349.	0.6	77
226	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. <i>Blood</i> , 2014, 123, 3567-3573.	0.6	76
227	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. <i>Blood</i> , 2009, 113, 2298-2301.	0.6	75
228	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
229	Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. <i>British Journal of Haematology</i> , 1993, 83, 158-165.	1.2	74
230	Impact of whole genome amplification on analysis of copy number variants. <i>Nucleic Acids Research</i> , 2008, 36, e80-e80.	6.5	74
231	High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. <i>Blood Advances</i> , 2018, 2, 2755-2765.	2.5	74
232	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012, 119, 3757-3766.	0.6	72
233	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>American Journal of Clinical Pathology</i> , 2011, 135, 54-61.	0.4	71
234	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	2.0	71

#	ARTICLE	IF	CITATIONS
235	Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. <i>Haematologica</i> , 2011, 96, 1002-1007.	1.7	69
236	A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. <i>Blood</i> , 2014, 123, 3914-3924.	0.6	69
237	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	0.6	68
238	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. <i>Clinical Cancer Research</i> , 2011, 17, 3727-3732.	3.2	68
239	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , 2016, 127, 2203-2213.	0.6	68
240	Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. <i>Blood</i> , 2015, 125, 999-1005.	0.6	67
241	Observation as the initial management strategy in patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2489-2495.	0.6	67
242	Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2000, 25, 605-612.	1.3	66
243	Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. <i>Annals of Oncology</i> , 2007, 18, 535-540.	0.6	66
244	Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 415-422.	1.2	66
245	The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases. <i>Leukemia and Lymphoma</i> , 2004, 45, 519-528.	0.6	65
246	Array-based DNA methylation profiling in follicular lymphoma. <i>Leukemia</i> , 2009, 23, 1858-1866.	3.3	65
247	Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. <i>Annals of Hematology</i> , 2015, 94, 1839-1843.	0.8	64
248	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
249	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1102-1109.	0.6	63
250	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. <i>Haematologica</i> , 2010, 95, 96-101.	1.7	63
251	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1322-1330.	2.1	63
252	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479.	2.2	63

#	ARTICLE	IF	CITATIONS
253	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2005, 23, 7994-8002.	0.8	62
254	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , 2017, 130, 1819-1831.	0.6	62
255	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	2.5	62
256	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood</i> , 2014, 123, 1665-1673.	0.6	61
257	TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4949-4952.	0.6	60
258	High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. <i>Oncogene</i> , 2015, 34, 1231-1240.	2.6	60
259	Aberrant expression of T-plastin in Sezary cells. <i>Cancer Research</i> , 2003, 63, 7122-7.	0.4	60
260	Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. <i>British Journal of Haematology</i> , 2015, 169, 520-527.	1.2	58
261	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 203-214.	1.2	58
262	Blastic Mantle Cell Leukemia: An Unusual Presentation of Blastic Mantle Cell Lymphoma. <i>Modern Pathology</i> , 2000, 13, 825-833.	2.9	57
263	Hypoxia-Inducible Factor-1 $\hat{\pm}$ Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	0.8	57
264	Lymphoma stem cells: enough evidence to support their existence?. <i>Haematologica</i> , 2010, 95, 293-302.	1.7	57
265	Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. <i>Annals of Oncology</i> , 2011, 22, 1164-1169.	0.6	57
266	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	3.3	57
267	Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases. <i>Leukemia and Lymphoma</i> , 2004, 45, 1881-1885.	0.6	56
268	The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project. <i>Annals of Oncology</i> , 2009, 20, 715-721.	0.6	56
269	The significance of <i>TP53</i> in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. <i>British Journal of Haematology</i> , 2009, 146, 257-269.	1.2	56
270	Duodenal follicular lymphoma: Comprehensive gene expression analysis with insights into pathogenesis. <i>Cancer Science</i> , 2014, 105, 608-615.	1.7	56

#	ARTICLE	IF	CITATIONS
271	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2493-2500.	0.8	56
272	Identification of high-risk <i>DUSP22</i> -rearranged <i>ALK</i> -negative anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e28-e31.	1.2	56
273	Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. <i>Leukemia and Lymphoma</i> , 2005, 46, 1721-1727.	0.6	55
274	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019, 104, e558-e561.	1.7	55
275	Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 783-791.	0.6	54
276	Evaluation of the International Prognostic Score (IPS ^{v7}) and a Simpler Prognostic Score (IPS ^{v3}) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	1.2	54
277	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. <i>Haematologica</i> , 2009, 94, 423-427.	1.7	53
278	Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-10.	0.6	53
279	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53
280	IL10 receptor is a novel therapeutic target in DLBCLs. <i>Leukemia</i> , 2015, 29, 1684-1694.	3.3	53
281	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	1.7	52
282	Can histologic transformation of follicular lymphoma be predicted and prevented?. <i>Blood</i> , 2017, 130, 258-266.	0.6	52
283	Clinical Utility of Heteroduplex Analysis of TCR Gamma Gene Rearrangements in the Diagnosis of T-Cell Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 1997, 108, 295-301.	0.4	51
284	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 693-701.	0.6	51
285	High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 669-681.	1.5	51
286	GBV _B /hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. <i>International Journal of Cancer</i> , 2010, 126, 2885-2892.	2.3	51
287	A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 680-686.	1.2	51
288	Tumor-associated macrophages in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2015, 100, 143-145.	1.7	51

#	ARTICLE	IF	CITATIONS
289	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018, 9, 222.	5.8	51
290	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	51
291	Bone Marrow Involvement in T-Cell-Rich B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 1997, 108, 570-578.	0.4	50
292	Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1038-1048.	1.5	50
293	Macrophages predict treatment outcome in Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 186-189.	1.7	50
294	Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65.	1.2	50
295	Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. <i>Cancer</i> , 2012, 118, 4156-4165.	2.0	49
296	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018, 132, 1695-1702.	0.6	49
297	The treatment of primary central nervous system lymphoma in 122 immunocompetent patients. <i>Cancer</i> , 2005, 103, 1008-1017.	2.0	48
298	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3722-3733.	0.8	48
299	Systemic anaplastic large-cell lymphoma: Results from the non-Hodgkin's lymphoma classification project. <i>American Journal of Hematology</i> , 2001, 67, 172-178.	2.0	47
300	Low-Grade Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 203-220.	0.9	47
301	Recurrent genomic rearrangements in primary testicular lymphoma. <i>Journal of Pathology</i> , 2015, 236, 136-141.	2.1	47
302	Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. <i>Blood</i> , 2016, 128, 1206-1213.	0.6	47
303	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47
304	Multicolor Karyotyping and Clinicopathological Analysis of Three Intravascular Lymphoma Cases. <i>Modern Pathology</i> , 2003, 16, 716-724.	2.9	46
305	Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2004, 127, 311-321.	1.2	46
306	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	15.2	46

#	ARTICLE	IF	CITATIONS
307	Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 4089-94.	0.4	46
308	<i>JUNB</i> , <i>DUSP2</i> , <i>SGK1</i> , <i>SOCS1</i> and <i>CREBBP</i> are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 330-337.	1.7	45
309	Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 574-580.	0.4	44
310	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. <i>Haematologica</i> , 2010, 95, 2157-2160.	1.7	44
311	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 768-775.	2.1	44
312	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	1.7	44
313	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. <i>Blood</i> , 2020, 136, 572-584.	0.6	44
314	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. <i>Leukemia and Lymphoma</i> , 2007, 48, 542-546.	0.6	43
315	Atypical Lymphoid Hyperplasia Mimicking Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 729-745.	0.9	43
316	Follicular Lymphoma of the Thyroid Gland. <i>American Journal of Surgical Pathology</i> , 2009, 33, 22-34.	2.1	43
317	The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. <i>Annals of Oncology</i> , 2016, 27, 1095-1099.	0.6	43
318	Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- κ B, p53, bax, and p27 levels. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 749-758.	1.9	42
319	Genomic profiles of MALT lymphomas: variability across anatomical sites. <i>Haematologica</i> , 2011, 96, 1064-1066.	1.7	42
320	Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). <i>Leukemia and Lymphoma</i> , 2014, 55, 768-772.	0.6	42
321	ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. <i>Leukemia</i> , 2005, 19, 1839-1840.	3.3	41
322	<i>MYD88</i> somatic mutations in MALT lymphomas. <i>British Journal of Haematology</i> , 2012, 158, 662-664.	1.2	41
323	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
324	Involvement of the X chromosome in non-Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 246-257.	1.5	40

#	ARTICLE	IF	CITATIONS
325	Emerging prognostic factors in diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2004, 16, 436-441.	1.1	40
326	The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. <i>Annals of Oncology</i> , 2014, 25, 669-674.	0.6	40
327	Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. <i>British Journal of Haematology</i> , 2003, 122, 745-759.	1.2	39
328	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 341-348.	0.2	39
329	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
330	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , 2018, 131, 2036-2046.	0.6	39
331	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
332	Anaplastic large cell lymphoma: a clinicopathologic analysis. , 1999, 17, 137-148.		37
333	Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. <i>British Journal of Haematology</i> , 2005, 128, 792-796.	1.2	37
334	Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 414-423.	1.5	37
335	Genetic Variation in H2AFX Contributes to Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1098-1106.	1.1	37
336	MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2903-2911.	0.8	37
337	Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 1395-1402.	0.6	36
338	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	1.5	36
339	Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2010, 21, 11-22.	0.8	36
340	Automated Analysis of Multidimensional Flow Cytometry Data Improves Diagnostic Accuracy Between Mantle Cell Lymphoma and Small Lymphocytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 75-85.	0.4	36
341	Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. <i>Annals of Oncology</i> , 2013, 24, 428-432.	0.6	36
342	Anxiety and Health-Related Quality of Life Among Patients With Low Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	0.8	36

#	ARTICLE	IF	CITATIONS
343	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016, 173, 867-875.	1.2	36
344	Evidence for Early Infection of Nonneoplastic Natural Killer Cells by Epstein-Barr Virus. <i>Journal of Virology</i> , 2002, 76, 11139-11142.	1.5	35
345	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 3118-3129.	0.6	35
346	Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Blood</i> , 2007, 110, 389-389.	0.6	35
347	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	1.1	34
348	Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas. <i>British Journal of Haematology</i> , 1999, 105, 437-440.	1.2	33
349	Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3396-3401.	0.8	33
350	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33
351	Impaired functional responses in follicular lymphoma CD8 ⁺ TIM-3 ⁺ T lymphocytes following TCR engagement. <i>OncImmunology</i> , 2016, 5, e1224044.	2.1	32
352	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 324-332.	0.6	32
353	Frequent association of t(3;14) or variant with other lymphoma-specific translocations. <i>British Journal of Haematology</i> , 1995, 89, 569-575.	1.2	31
354	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). <i>Cancer</i> , 2016, 122, 2996-3004.	2.0	31
355	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018, 131, 226-235.	0.6	31
356	Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 375-381.	1.5	30
357	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. <i>Cancer Research</i> , 2008, 68, 3361-3369.	0.4	30
358	Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. <i>Leukemia Research</i> , 2006, 30, 449-457.	0.4	29
359	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.4	29
360	Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study. <i>Blood</i> , 2008, 112, 975-975.	0.6	29

#	ARTICLE	IF	CITATIONS
361	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. <i>Blood</i> , 2012, 120, 303-303.	0.6	29
362	Heavy multinodular cutaneous lymphoid infiltrates: clinicopathologic features and B-cell clonality. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 159-167.	0.7	28
363	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. <i>Haematologica</i> , 2010, 95, 2056-2062.	1.7	28
364	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , 2009, 114, 408-408.	0.6	28
365	Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma*. <i>British Journal of Haematology</i> , 2006, 133, 634-637.	1.2	27
366	Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. <i>International Journal of Cancer</i> , 2008, 122, 630-633.	2.3	27
367	Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. <i>BMC Medical Genetics</i> , 2009, 10, 117.	2.1	27
368	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Leukemia</i> , 2014, 28, 362-372.	3.3	27
369	Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 394-394.	0.6	27
370	Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 60-65.	1.5	26
371	Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	2.3	26
372	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236.	3.2	26
373	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
374	Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. <i>British Journal of Haematology</i> , 2017, 179, 508-510.	1.2	26
375	Molecular Methods for Detecting t(11;14) Translocations in Mantle-Cell Lymphomas. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 209-214.	2.1	25
376	Immunohistochemical investigation of SV40 large T antigen in Hodgkin and non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2004, 112, 533-535.	2.3	25
377	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	3.2	25
378	Lymphotoxin network pathways shape the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 222-229.	2.4	25

#	ARTICLE	IF	CITATIONS
379	Phase II Trial of Bortezomib in Mantle Cell Lymphoma.. Blood, 2004, 104, 608-608.	0.6	25
380	Immunohistochemical Analysis of bc1-2, bax, mcl-1, and bc1-X Expression in Ovarian Surface Epithelial Tumors. International Journal of Gynecological Pathology, 1998, 17, 255-260.	0.9	24
381	t(2;5) Positive Lymphoma with Peripheral Blood Involvement. Leukemia and Lymphoma, 1998, 28, 415-422.	0.6	24
382	An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood, 2015, 125, 959-966.	0.6	24
383	PATHOLOGIC PROGNOSTIC FACTORS IN DIFFUSE AGGRESSIVE NON-HODGKIN'S LYMPHOMA. Hematology/Oncology Clinics of North America, 1997, 11, 847-862.	0.9	23
384	Clinical Significance of the t(14;18) And BCL2 Overexpression in Follicular Large Cell Lymphoma. Leukemia and Lymphoma, 2000, 36, 513-523.	0.6	23
385	Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia, 2005, 19, 856-861.	3.3	23
386	Phase II study of denileukin diftiox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497. Leukemia and Lymphoma, 2007, 48, 2397-2402.	0.6	23
387	Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component. American Journal of Surgical Pathology, 2011, 35, 177-189.	2.1	23
388	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncolmmunology, 2017, 6, e1321184.	2.1	23
389	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. Blood, 2013, 122, 1-1.	0.6	23
390	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood, 2014, 124, 392-392.	0.6	23
391	Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia and Lymphoma, 2011, 52, 24-33.	0.6	22
392	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Advances, 2019, 3, 3953-3961.	2.5	22
393	Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. Genes Chromosomes and Cancer, 2002, 34, 201-210.	1.5	21
394	Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplantation, 2008, 42, 601-608.	1.3	21
395	Prognostic biomarkers in malignant lymphomas. Leukemia and Lymphoma, 2010, 51, 11-19.	0.6	21
396	Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases. British Journal of Haematology, 2017, 178, 442-447.	1.2	21

#	ARTICLE	IF	CITATIONS
397	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2020, 44, 657-664.	2.1	21
398	Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma. PLoS ONE, 2012, 7, e31560.	1.1	21
399	Lymphoma With Follicular and Monocytoid B-Cell Components. American Journal of Clinical Pathology, 2000, 114, 516-522.	0.4	20
400	Classification of Non-Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2008, 22, 781-805.	0.9	20
401	CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry Part B - Clinical Cytometry, 2012, 82B, 112-119.	0.7	20
402	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. British Journal of Haematology, 2017, 176, 234-240.	1.2	20
403	CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial. Blood, 2012, 120, 1638-1638.	0.6	20
404	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. Blood, 2015, 126, 579-579.	0.6	20
405	T-cell receptor variable region gene expression in cutaneous T-cell lymphomas. Journal of Cutaneous Pathology, 1992, 19, 21-26.	0.7	19
406	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I-II) diffuse large B-cell non-Hodgkin lymphoma: ECOG 3402. British Journal of Haematology, 2015, 170, 679-686.	1.2	19
407	Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake. Clinical Cancer Research, 2015, 21, 4-6.	3.2	19
408	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. , 2019, 7, 70.		19
409	Characterization of DLBCL with a PMBL gene expression signature. Blood, 2021, 138, 136-148.	0.6	19
410	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. Blood, 2018, 132, 998-998.	0.6	19
411	Simultaneous Development of Diffuse Immunoblastic Lymphoma in Recipients of Renal Transplants From a Single Cadaver Donor: Transmission of Epstein-Barr Virus and Triggering by OKT3. American Journal of Kidney Diseases, 1994, 23, 130-134.	2.1	18
412	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica, 2009, 94, 596-598.	1.7	18
413	A roadmap for discovery and translation in lymphoma. Blood, 2015, 125, 2175-2177.	0.6	18
414	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood, 2021, 137, 2196-2208.	0.6	18

#	ARTICLE	IF	CITATIONS
415	A Randomized Phase III Trial of ABVD Vs. Stanford V + ¹⁷ Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010, 116, 415-415.	0.6	18
416	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. <i>Blood</i> , 2014, 124, 628-628.	0.6	18
417	Model-based clustering of array CGH data. <i>Bioinformatics</i> , 2009, 25, i30-i38.	1.8	17
418	Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. <i>Blood</i> , 2010, 116, 6146-6147.	0.6	17
419	Newly Identified Mechanisms in B-Cell Non-Hodgkin Lymphomas Uncovered by Next-Generation Sequencing. <i>Seminars in Hematology</i> , 2013, 50, 303-313.	1.8	17
420	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. <i>Blood Advances</i> , 2021, 5, 1483-1489.	2.5	17
421	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. <i>Haematologica</i> , 2017, 102, e404-e406.	1.7	16
422	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. <i>Haematologica</i> , 2018, 103, e590-e593.	1.7	16
423	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. <i>Lupus Science and Medicine</i> , 2019, 6, e000324.	1.1	16
424	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
425	Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL). <i>Blood</i> , 2010, 116, 113-113.	0.6	16
426	Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma. <i>Human Pathology</i> , 2003, 34, 789-791.	1.1	15
427	Molecular Pathogenesis of Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S13-S20.	0.6	15
428	Selective ablation of the YxxM motif of IL-7R α suppresses lymphomagenesis but maintains lymphocyte development. <i>Oncogene</i> , 2010, 29, 3854-3864.	2.6	15
429	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013, 133, 2852-2863.	2.3	15
430	Next-generation Sequencing Discoveries in Lymphoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 110-116.	2.4	15
431	XIV. The pathology of transformation of indolent B cell lymphomas. <i>Hematological Oncology</i> , 2015, 33, 75-79.	0.8	15
432	Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.. <i>Blood</i> , 2006, 108, 812-812.	0.6	15

#	ARTICLE	IF	CITATIONS
433	Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). <i>Molecular Cancer</i> , 2010, 9, 14.	7.9	14
434	Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. <i>Leukemia</i> , 2017, 31, 517-519.	3.3	14
435	Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).. <i>Blood</i> , 2007, 110, 3420-3420.	0.6	14
436	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. <i>Blood</i> , 2007, 110, 790-790.	0.6	14
437	Molecular Signatures of Lymphoma. <i>International Journal of Hematology</i> , 2004, 80, 401-409.	0.7	13
438	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
439	Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1256-1259.	0.6	13
440	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 809-809.	0.6	13
441	B Cells With High Side Scatter Parameter by Flow Cytometry Correlate With Inferior Survival in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 805-814.	0.4	12
442	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 620-629.	1.1	12
443	Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by... <i>Blood</i> , 2005, 106, 18-18.	0.6	12
444	A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1093-1093.	0.6	12
445	Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.. <i>Blood</i> , 2009, 114, 268-268.	0.6	12
446	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
447	Cytogenetic findings in reactive lymphoid hyperplasia: Significance of non-clonal t(3;14) and t(3;22). <i>American Journal of Hematology</i> , 2002, 70, 133-138.	2.0	11
448	Lifetime Physical Activity and the Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 873-877.	1.1	11
449	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. <i>Haematologica</i> , 2016, 101, e411-e414.	1.7	11
450	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	0.8	11

#	ARTICLE	IF	CITATIONS
451	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11
452	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. <i>Blood</i> , 2007, 110, 348-348.	0.6	11
453	Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1. <i>Leukemia</i> , 2002, 16, 276-283.	3.3	10
454	Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 872-879.	0.6	10
455	Impact of age on genetics and treatment efficacy in follicular lymphoma. <i>Haematologica</i> , 2018, 103, e364-e367.	1.7	10
456	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
457	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , 2014, 124, 3016-3016.	0.6	10
458	Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development. <i>PLoS ONE</i> , 2013, 8, e75170.	1.1	10
459	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures. <i>Blood</i> , 2009, 114, 619-619.	0.6	10
460	Translocation t(3;3)(q21;q26) and thrombocytosis. <i>Cancer Genetics and Cytogenetics</i> , 1986, 22, 365.	1.0	9
461	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. <i>Leukemia and Lymphoma</i> , 2009, 50, 1875-1878.	0.6	9
462	Convergence of risk prediction models in follicular lymphoma. <i>Haematologica</i> , 2019, 104, e252-e255.	1.7	9
463	Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 1466-1471.	1.7	9
464	Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2004, 104, 26-26.	0.6	9
465	The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. <i>Blood</i> , 2009, 114, 1661-1661.	0.6	9
466	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. <i>Blood</i> , 2010, 116, 854-854.	0.6	9
467	Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 153-153.	0.6	9
468	Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma. <i>Blood</i> , 1997, 90, 244-251.	0.6	9

#	ARTICLE	IF	CITATIONS
469	A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8615-TPS8615.	0.8	9
470	Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. <i>Blood</i> , 2021, , .	0.6	9
471	A systematic evaluation of the <i>ataxia telangiectasia mutated</i> gene does not show an association with non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2007, 121, 1967-1975.	2.3	8
472	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.2	8
473	Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma. <i>Blood</i> , 2008, 112, 4459-4459.	0.6	8
474	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010, 116, 416-416.	0.6	8
475	Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible. <i>Blood</i> , 2014, 124, 3069-3069.	0.6	8
476	The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 495-495.	0.6	8
477	Histopathologic, immunophenotypic and genotypic analyses in ocular adnexal lymphoproliferative disorders. <i>Australian and New Zealand Journal of Ophthalmology</i> , 1992, 20, 247-251.	0.4	7
478	Bcl-6 and Lymphoproliferative Disorders. <i>Leukemia and Lymphoma</i> , 1997, 26, 515-525.	0.6	7
479	SNP Analysis of Minimally Evolved t(14;18)(q32;q21)-Positive Follicular Lymphomas Reveals a Common Copy-Neutral Loss of Heterozygosity Pattern. <i>Cytogenetic and Genome Research</i> , 2012, 136, 38-43.	0.6	7
480	Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).. <i>Blood</i> , 2005, 106, 492-492.	0.6	7
481	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 333-333.	0.6	7
482	Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. <i>Blood</i> , 2006, 108, 3662-3662.	0.6	7
483	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. <i>Blood</i> , 2007, 110, 360-360.	0.6	7
484	Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 299-306.	0.9	6
485	Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas. <i>Molecular Cancer</i> , 2008, 7, 12.	7.9	6
486	Gene expression signatures in follicular lymphoma: are they ready for the clinic?. <i>Haematologica</i> , 2008, 93, 982-987.	1.7	6

#	ARTICLE	IF	CITATIONS
487	VII. The role of the microenvironment in lymphoid cancers. <i>Annals of Oncology</i> , 2011, 22, iv47-iv50.	0.6	6
488	Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 816-816.	0.6	6
489	Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 473-473.	0.6	6
490	The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis. <i>Blood</i> , 2012, 120, 1531-1531.	0.6	6
491	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. <i>Blood</i> , 2012, 120, 1545-1545.	0.6	6
492	Clinicopathological Analysis of Follicular Lymphoma with a Polyploid Karyotype. <i>Leukemia and Lymphoma</i> , 1998, 28, 383-389.	0.6	5
493	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 113-117.	1.4	5
494	The Tumor Microenvironment Measured by Flow Cytometry Predicts Overall Survival (OS) and Transformation Risk (TR) in Follicular Lymphoma.. <i>Blood</i> , 2006, 108, 2406-2406.	0.6	5
495	Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome. <i>Blood</i> , 2008, 112, 3777-3777.	0.6	5
496	CD30 Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1558-1558.	0.6	5
497	Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia. <i>Blood</i> , 2013, 122, 1788-1788.	0.6	5
498	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	0.6	5
499	Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4345-4345.	0.6	5
500	Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma. <i>Blood</i> , 2013, 122, 507-507.	0.6	5
501	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 703-703.	0.6	5
502	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	0.6	5
503	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 2919-2919.	0.6	5
504	Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections. <i>Journal of Hematopathology</i> , 2010, 3, 3-9.	0.2	4

#	ARTICLE	IF	CITATIONS
505	Controversies in BMT for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S26-S32.	2.0	4
506	Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e199-e202.	1.7	4
507	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <i>Blood Advances</i> , 2021, 5, 3647-3655.	2.5	4
508	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
509	The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo. <i>Blood</i> , 2008, 112, 707-707.	0.6	4
510	The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.. <i>Blood</i> , 2009, 114, 1554-1554.	0.6	4
511	Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. <i>Blood</i> , 2010, 116, 1751-1751.	0.6	4
512	Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404). <i>Blood</i> , 2012, 120, 687-687.	0.6	4
513	CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression. <i>Blood</i> , 2014, 124, 1681-1681.	0.6	4
514	Inactivating Gene Alterations of MHC Class II Transactivator CIITA Are Recurrent in Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 437-437.	0.6	4
515	Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma. <i>Blood</i> , 2012, 120, 682-682.	0.6	4
516	Stem cells in Hodgkin lymphoma?. <i>Blood</i> , 2009, 113, 5694-5694.	0.6	3
517	Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000679.	0.5	3
518	Transformed Lymphoma: Incidence and Long-Term Outcome.. <i>Blood</i> , 2004, 104, 3253-3253.	0.6	3
519	The Architectural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 358-358.	0.6	3
520	Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404. <i>Blood</i> , 2008, 112, 372-372.	0.6	3
521	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. <i>Blood</i> , 2009, 114, 133-133.	0.6	3
522	Tyrosine 641 of the EZH2 Oncogene Is Frequently Mutated in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin.. <i>Blood</i> , 2009, 114, 139-139.	0.6	3

#	ARTICLE	IF	CITATIONS
523	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603.	0.6	3
524	Mutated EZH2 Collaborates with Myc in Inducing Lymphoma in a Mouse Model. <i>Blood</i> , 2011, 118, 227-227.	0.6	3
525	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. <i>Blood</i> , 2011, 118, 780-780.	0.6	3
526	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
527	Genomic Rearrangements Involving Programmed Death Ligands Are Recurrent In Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 635-635.	0.6	3
528	IDH2 R172 Mutations Define a Unique Subgroup of Patients in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 3580-3580.	0.6	3
529	Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 2699-2699.	0.6	3
530	Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of Eat1 Oncogenesis. <i>Blood</i> , 2015, 126, 575-575.	0.6	3
531	Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4237-4237.	0.6	3
532	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw250.	3.0	2
533	Anaplastic large cell lymphoma: a clinicopathologic analysis. <i>Hematological Oncology</i> , 1999, 17, 137-148.	0.8	2
534	Burkitt's Lymphoma. , 2011, , 391-409.		2
535	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1560-1560.	0.6	2
536	TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP. <i>Blood</i> , 2019, 134, 3964-3964.	0.6	2
537	Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphoblastic Lymphoma (T-LBL) : An Intention to Treat Analysis.. <i>Blood</i> , 2004, 104, 900-900.	0.6	2
538	Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 356-356.	0.6	2
539	Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2007, 110, 3040-3040.	0.6	2
540	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , 2007, 110, 52-52.	0.6	2

#	ARTICLE	IF	CITATIONS
541	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. Blood, 2007, 110, 692-692.	0.6	2
542	Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 477-477.	0.6	2
543	Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 479-479.	0.6	2
544	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. Blood, 2009, 114, 3944-3944.	0.6	2
545	Incorporation of ABVD Increases Cure Rates of Patients with Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL). Blood, 2010, 116, 3887-3887.	0.6	2
546	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. Blood, 2010, 116, 417-417.	0.6	2
547	Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors. Blood, 2011, 118, 96-96.	0.6	2
548	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. Blood, 2012, 120, 2687-2687.	0.6	2
549	EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC).. Journal of Clinical Oncology, 2016, 34, 7569-7569.	0.8	2
550	CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.. Blood, 2007, 110, 686-686.	0.6	2
551	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. Blood, 2007, 110, 2631-2631.	0.6	2
552	Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma. Blood, 2008, 112, 2815-2815.	0.6	2
553	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. Blood, 2009, 114, 622-622.	0.6	2
554	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, 2010, 116, 2005-2005.	0.6	2
555	SOX11 Directly Represses Wnt/ β -Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment. Blood, 2012, 120, 895-895.	0.6	2
556	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. Blood, 2013, 122, 3045-3045.	0.6	2
557	Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. Blood, 2013, 122, 847-847.	0.6	2
558	Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement. Blood, 2007, 109, 844-844.	0.6	1

#	ARTICLE	IF	CITATIONS
559	Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma. PLoS ONE, 2013, 8, e74619.	1.1	1
560	Reply to M. Gleeson et al. Journal of Clinical Oncology, 2015, 33, 3216-3217.	0.8	1
561	Involvement of the X chromosome in non-Hodgkin lymphoma. , 2000, 28, 246.		1
562	Diffuse Aggressive B-Cell Lymphomas. , 2012, , 261-292.		1
563	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. Blood, 2018, 132, 1615-1615.	0.6	1
564	Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray. Blood, 2018, 132, 348-348.	0.6	1
565	The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL. Blood, 2018, 132, 921-921.	0.6	1
566	Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).. Blood, 2004, 104, 3259-3259.	0.6	1
567	Survival of Limited Stage Peripheral T-Cell Lymphoma Is Similar To Diffuse Large B-Cell Lymphoma.. Blood, 2005, 106, 2817-2817.	0.6	1
568	Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics.. Blood, 2005, 106, 604-604.	0.6	1
569	Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration.. Blood, 2006, 108, 2049-2049.	0.6	1
570	Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.. Blood, 2008, 112, 2173-2173.	0.6	1
571	Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas. Blood, 2008, 112, 622-622.	0.6	1
572	A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma.. Blood, 2009, 114, 1941-1941.	0.6	1
573	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. Blood, 2009, 114, 2923-2923.	0.6	1
574	Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing. Blood, 2010, 116, 804-804.	0.6	1
575	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial. Blood, 2011, 118, 430-430.	0.6	1
576	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. Blood, 2014, 124, 1624-1624.	0.6	1

#	ARTICLE	IF	CITATIONS
577	Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 2976-2976.	0.6	1
578	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. <i>Blood</i> , 2014, 124, 3018-3018.	0.6	1
579	Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype. <i>Blood</i> , 2015, 126, 109-109.	0.6	1
580	Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 571-571.	0.6	1
581	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2686-2686.	0.6	1
582	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.	0.6	1
583	Rapid, real-time central pathology review for E1412: A novel and successful paradigm for future National Clinical Trials Network diffuse large B cell lymphoma studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7547-7547.	0.8	1
584	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7548-7548.	0.8	1
585	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. <i>Blood</i> , 2004, 104, 415-415.	0.6	1
586	Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.. <i>Blood</i> , 2007, 110, 1559-1559.	0.6	1
587	High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 183-183.	0.6	1
588	Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.. <i>Blood</i> , 2007, 110, 50-50.	0.6	1
589	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2008, 112, 475-475.	0.6	1
590	Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 522-522.	0.6	1
591	High Prevalence of TERT Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 3126-3126.	0.6	1
592	TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.. <i>Blood</i> , 2009, 114, 1919-1919.	0.6	1
593	Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.. <i>Blood</i> , 2009, 114, 407-407.	0.6	1
594	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011, 118, 87-87.	0.6	1

#	ARTICLE	IF	CITATIONS
595	Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 242-242.	0.6	1
596	Origin of the Hodgkin/Reed-Sternberg Cells in Chronic Lymphocytic Leukemia With "Hodgkin's Transformation". <i>Blood</i> , 1998, 91, 1757-1761.	0.6	1
597	Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas. <i>Blood</i> , 2014, 124, 271-271.	0.6	1
598	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq0 0 0 rgBT.4 Overlook 10 Tf 50		
599	Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL). <i>Blood</i> , 2015, 126, 2667-2667.	0.6	1
600	Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 607-607.	0.6	1
601	Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition. <i>Blood</i> , 2018, 132, 669-669.	0.6	1
602	Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome. <i>Blood</i> , 2019, 134, 922-922.	0.6	1
603	The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-34.	0.6	1
604	Spontaneous regression of chemotherapy-refractory non-hodgkin's lymphoma preceding the development of secondary leukaemia. <i>Leukemia and Lymphoma</i> , 1996, 20, 351-353.	0.6	0
605	Leukaemic infiltration of an adenocarcinoma effusion. <i>British Journal of Haematology</i> , 2001, 112, 257-257.	1.2	0
606	The Role of Hepatitis C Virus Infection and Non-Hodgkin Lymphoma in Canada. <i>American Journal of Epidemiology</i> , 2006, 163, S89-S89.	1.6	0
607	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, xi-xii.	0.9	0
608	9202 Long-term outcomes for patients with limited stage, follicular lymphoma: involved regional radiotherapy versus involved nodal radiotherapy. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 560-561.	2.2	0
609	Reply to L. Wannesson et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 336-337.	0.8	0
610	Implementing a Multi-analyte Immunohistochemistry Panel into a Drug Development Program. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 345-358.	0.1	0
611	Genome-wide <sc>DNA</sc> profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899.	1.2	0
612	Summary and Future Directions. <i>Seminars in Hematology</i> , 2015, 52, 143-147.	1.8	0

#	ARTICLE	IF	CITATIONS
613	9. The biology of primary mediastinal large B-cell lymphoma. , 2016, , 171-192.		0
614	CD5-positive diffuse large B-cell lymphoma: a distinct entity?. Advances in Anatomic Pathology, 2002, 9, 269-270.	2.4	0
615	HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.. Blood, 2004, 104, 3273-3273.	0.6	0
616	Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2004, 104, 3325-3325.	0.6	0
617	Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.. Blood, 2004, 104, 4553-4553.	0.6	0
618	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. Blood, 2004, 104, 697-697.	0.6	0
619	Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.. Blood, 2004, 104, 2764-2764.	0.6	0
620	Towards the Human Cancer Genome Project: A Sequence-Ready Physical Map of a Follicular Lymphoma Genome.. Blood, 2005, 106, 605-605.	0.6	0
621	CD56+ Monomorphic Enteropathy-Type T-Cell Lymphoma Is a Genetically Distinct Entity Characterized by 8q Gains and Lack of 1q and 5q Gains.. Blood, 2005, 106, 2840-2840.	0.6	0
622	BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells.. Blood, 2005, 106, 4392-4392.	0.6	0
623	Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. Blood, 2006, 108, 3139-3139.	0.6	0
624	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. Blood, 2006, 108, 2739-2739.	0.6	0
625	Bone Marow (BM) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Clinical Impact of Discordant Disease.. Blood, 2006, 108, 2031-2031.	0.6	0
626	Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.. Blood, 2006, 108, 3039-3039.	0.6	0
627	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. Blood, 2006, 108, 811-811.	0.6	0
628	Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).. Blood, 2006, 108, 2027-2027.	0.6	0
629	Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.. Blood, 2007, 110, 1563-1563.	0.6	0
630	Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMP.. Blood, 2007, 110, 2606-2606.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).. Blood, 2007, 110, 184-184.	0.6	0
632	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.. Blood, 2008, 112, 1786-1786.	0.6	0
633	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. Blood, 2008, 112, 2049-2049.	0.6	0
634	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. Blood, 2008, 112, 520-520.	0.6	0
635	Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. Blood, 2008, 112, 3782-3782.	0.6	0
636	Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner. Blood, 2008, 112, 804-804.	0.6	0
637	Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma.. Blood, 2009, 114, 439-439.	0.6	0
638	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.. Blood, 2009, 114, 620-620.	0.6	0
639	MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 624-624.	0.6	0
640	MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.. Blood, 2009, 114, 1100-1100.	0.6	0
641	FAS Mutations in Follicular Lymphoma Are Rare but Associated with Aggressive Clinical Behavior.. Blood, 2009, 114, 3967-3967.	0.6	0
642	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. Blood, 2009, 114, 2922-2922.	0.6	0
643	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	0.6	0
644	The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 4129-4129.	0.6	0
645	Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma. Blood, 2010, 116, 800-800.	0.6	0
646	Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets. Blood, 2010, 116, 632-632.	0.6	0
647	Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. Blood, 2010, 116, 1803-1803.	0.6	0
648	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. Blood, 2010, 116, 2006-2006.	0.6	0

#	ARTICLE	IF	CITATIONS
649	BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4187-4187.	0.6	0
650	CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. Blood, 2011, 118, 427-427.	0.6	0
651	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. Blood, 2011, 118, 435-435.	0.6	0
652	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. Blood, 2011, 118, 556-556.	0.6	0
653	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. Blood, 2011, 118, 585-585.	0.6	0
654	Mutations of STAT6 DNA Binding Domain Are Characteristic of PMBL and Belong to the Genetic Signature of This Entity.. Blood, 2012, 120, 2645-2645.	0.6	0
655	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545.	0.6	0
656	A 7-Genes MicroRNA Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis. Blood, 2012, 120, 1586-1586.	0.6	0
657	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. Blood, 2012, 120, 235-235.	0.6	0
658	Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) â€” A Heterogeneous Disorder with Improved Outcomes in the Modern Era. Blood, 2012, 120, 1602-1602.	0.6	0
659	Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells.. Blood, 2012, 120, 2333-2333.	0.6	0
660	FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma. Blood, 2012, 120, 1549-1549.	0.6	0
661	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. Blood, 2012, 120, 2648-2648.	0.6	0
662	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. Blood, 2012, 120, 3705-3705.	0.6	0
663	Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation. Blood, 2012, 120, 295-295.	0.6	0
664	Next-Generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation. Blood, 2012, 120, SCI-12-SCI-12.	0.6	0
665	Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model. Blood, 2013, 122, 346-346.	0.6	0
666	Predicting Cell Of Origin In Diffuse Large B-Cell Lymphoma By High Dimensional Flow Cytometry. Blood, 2013, 122, 4301-4301.	0.6	0

#	ARTICLE	IF	CITATIONS
667	Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival. Blood, 2013, 122, 500-500.	0.6	0
668	Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC). Blood, 2013, 122, 4369-4369.	0.6	0
669	The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience. Blood, 2013, 122, 4390-4390.	0.6	0
670	Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma. Blood, 2013, 122, 4232-4232.	0.6	0
671	Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in) Tj ETQq1 1 0.784314 rgBT /Overl	0.6	0
672	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue " An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	0.6	0
673	The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. Blood, 2013, 122, 1804-1804.	0.6	0
674	A Single-institution Perspective. American Journal of Surgical Pathology, 1996, 20, 373-375.	2.1	0
675	Histologic Features and Differential Diagnosis of Nodular Lymphocyte Predominance Hodgkin's Lymphoma (NLPHL). American Journal of Surgical Pathology, 1998, 22, 131-133.	2.1	0
676	Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells. , 2014, , .		0
677	Abstract 2945: Characterization of a novel protein-coding gene named TIHL (Translocated in Hodgkin's) Tj ETQq1 1 0.784314 rgBT /Ove		0
678	Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation. Blood, 2014, 124, 136-136.	0.6	0
679	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. Blood, 2014, 124, 1703-1703.	0.6	0
680	Genetic Alterations of the MHC Class II Transactivator CIITA Are Frequent in Primary Mediastinal Large B-Cell Lymphoma and Associated with Diminished MHC Class II Expression. Blood, 2014, 124, 3040-3040.	0.6	0
681	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. Blood, 2014, 124, 1667-1667.	0.6	0
682	Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience. Blood, 2014, 124, 3076-3076.	0.6	0
683	What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma?. Hematologic Malignancies, 2015, , 79-92.	0.2	0
684	Abstract A19: MALT1 inhibition as an anchor for combinatorial therapy of ABC-DLBCL.. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
685	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2015, 126, 3950-3950.	0.6	0
686	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. <i>Blood</i> , 2015, 126, 434-434.	0.6	0
687	Mass Cytometry Based Classification of Inter- and Intra-Tumoral Heterogeneity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3908-3908.	0.6	0
688	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. <i>Blood</i> , 2015, 126, 2702-2702.	0.6	0
689	Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study. <i>Blood</i> , 2015, 126, 3971-3971.	0.6	0
690	Genetic Alterations of $CI\pm 13$ Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 111-111.	0.6	0
691	Abstract IA18: Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma. , 2016, , .		0
692	Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7547-7547.	0.8	0
693	Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study. <i>Blood</i> , 2016, 128, 4145-4145.	0.6	0
694	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. <i>Blood</i> , 2016, 128, 735-735.	0.6	0
695	Revealing the Tumor Ecosystem in Follicular Lymphoma By Mass Cytometry. <i>Blood</i> , 2016, 128, 2939-2939.	0.6	0
696	The Role of UBR5 Mutations in the Pathogenesis of Mantle CELL Lymphoma. <i>Blood</i> , 2016, 128, 4124-4124.	0.6	0
697	Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1091-1091.	0.6	0
698	Characterization of Genomic Rearrangements Involving CIITA and SOCS1 Using Targeted Capture Sequencing of Archival Tissue Specimens. <i>Blood</i> , 2016, 128, 2925-2925.	0.6	0
699	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. <i>Blood</i> , 2016, 128, 4095-4095.	0.6	0
700	Abstract 2445: Integrative genetic analysis identifies therapeutic relevance of cell of origin-specific genetic alterations in diffuse large B-cell lymphoma. , 2017, , .		0
701	Single-Cell Profiling Reveals Distinct Tumor Subtypes and Their Associated T-Cell Environments in Follicular Lymphoma. <i>Blood</i> , 2018, 132, 1577-1577.	0.6	0
702	UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism. <i>Blood</i> , 2018, 132, 2849-2849.	0.6	0

#	ARTICLE	IF	CITATIONS
703	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157.	0.6	0
704	Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.. Journal of Clinical Oncology, 2019, 37, 6511-6511.	0.8	0
705	Abstract 3765: Somatic JAK-STAT mutations in subtypes of aggressive B-cell lymphomas with DLBCL morphology. , 2019, , .		0
706	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study. Blood, 2019, 134, 3475-3475.	0.6	0
707	Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 2763-2763.	0.6	0
708	Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma. Blood, 2019, 134, 1478-1478.	0.6	0
709	Distinguishing between immunophenotype and genotype in non-Hodgkin's lymphomas. Psychophysiology, 2003, 2, 443-4.	1.1	0
710	Molecular pathology of lymphoma. , 0, , 257-276.		0
711	Abstract 3480: <i>TMEM30A</i> loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. , 2019, , .		0